- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05679895
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)
April 2, 2024 updated by: OneChain Immunotherapeutics
Safety and Efficacy of hCD1a-CAR T (OC-1) Therapy, in Patients With Relapsed/Refractory (R/R) T-cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LL
First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wilmar Castillo
- Phone Number: 34 93 403 58 62
- Email: wilmar@onechaintx.com
Study Contact Backup
- Name: Laura Astier
- Email: laura.astier@bioclever.com
Study Locations
-
-
-
Barcelona, Spain
- Recruiting
- Hospital Clínic
-
Contact:
- Nuria Martinez
-
Barcelona, Spain
- Recruiting
- Hospital Sant Joan de Déu
-
Contact:
- Susana Rives
- Phone Number: 34 93 280 40 00
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Children older than 2 years or adults, male and female in both groups.
- Patients CD1a antigen blast expression ≥20% at inclusion, either immunophenotypically (flow cytometry) or histologically confirmed.
R/R CD1a-positive T-ALL/LL patients, including morphologic or MRD-detectable (≥1x10-4) bone marrow and/or extramedullary relapses after 2 therapy lines:
- Relapse after allogeneic haematopoietic stem cell transplantation (allo-HSCT)
- Primary refractoriness, defined as either morphologic persistence or detectable MRD (≥1x10-4) after two standard therapy lines, making the patient not candidate for allo-HSCT.
- Refractory first relapse.
- Second or further relapse.
- Patient without reproductive capacity or else, commitment to the use of a highly effective method of contraception during the study.
Exclusion Criteria:
- Limiting organ dysfunction, such as uncontrolled cardiac (e.g., depressed left ventricular ejection fraction (LVEF), <45%), pulmonary, liver, renal or CNS dysfunction.
- Allo-HSCT within a timeframe <3 months, or requiring continued immunosuppressive treatment for graft versus host disease (GvHD).
- Uncontrolled epilepsy or underlying central nervous system (CNS) severe disease.
- Active bacterial, fungal or viral infection not controlled by adequate treatment.
- Known HIV, active hepatitis B (HBV), or hepatitis C virus (HCV) infection.
- Women who are pregnant (positive urine/blood pregnancy test) or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: CD1a-CAR T
CD1a CAR T cells transduced with a lentiviral vector to express CD1a chimeric receptor domain on T cells administered with a dose-escalation approach.
|
Autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express CD1a chimeric antigen receptor administered by intravenous infusion following a dose-escalation approach
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events grade III-IV
Time Frame: 1 year particularly the first 28 days after infusion
|
Number of adverse events grade III-IV using common toxicity criteria (CTC)
|
1 year particularly the first 28 days after infusion
|
Incidence of severe Cytokine release syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS)
Time Frame: 1 year particularly the first 28 days after infusion
|
Incidence of severe Cytokine release syndrome (CRS) (≥ grade III) and Immune effector cell-associated neurotoxicity syndrome (ICANS) (≥ grade II)
|
1 year particularly the first 28 days after infusion
|
Non-relapse treatment-related mortality (NRM)
Time Frame: 1 year
|
Non-relapse treatment-related mortality (NRM)
|
1 year
|
Number of adverse events of special interest (AESI)
Time Frame: 1 year
|
Number of adverse events of special interest (AESI)
|
1 year
|
Assessment of the immunological homeostasis
Time Frame: 1 year
|
Assessment of the immunological homeostasis, through the identification of lymphocytes subpopulations by flow cytometry at each study timepoint.
|
1 year
|
Incidence of the treatment-related dermatological events
Time Frame: 1 year
|
Incidence of the treatment-related dermatological events
|
1 year
|
Number of patients developing dose limiting toxicity (DLT)
Time Frame: first 28 days after infusion
|
Number of patients developing dose limiting toxicity (DLT)
|
first 28 days after infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission rate
Time Frame: 1 year
|
Percentage of patients presenting complete response (CR) or incomplete count recovery (CRi) at any point after treatment.
|
1 year
|
Response rates
Time Frame: 1 year
|
Percentage of patients presenting CR, CRi, Complete remission duration (CRD), morphologic leukaemia-free status (MLFS), and no remission (NR).
|
1 year
|
Duration of remission
Time Frame: 1 year
|
The duration of the remission will be assessed from the first documented date of remission status until progression (in days)
|
1 year
|
Minimal residual disease (MRD) response
Time Frame: 1 year
|
Minimal residual disease (MRD) response by flow cytometry: blast count among patients presenting bone marrow complete response (sensitivity 10-4).
|
1 year
|
Progression-free survival (PFS)
Time Frame: 1 year
|
time since the first OC-1 administration to the documented loss of response.
|
1 year
|
Overall survival
Time Frame: 1 year
|
Overall survival time since first OC-1 administration to date of death.
|
1 year
|
Persistence of OC-1
Time Frame: 1 year
|
• Persistence of OC-1, as determined by flow cytometry and quantitative analysis by qPCR.
Genomic copy number integrations of the CAR in peripheral blood (PB) T cells and percentage of CD1a CAR-expressing T cells.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 31, 2023
Primary Completion (Estimated)
June 25, 2025
Study Completion (Estimated)
January 25, 2026
Study Registration Dates
First Submitted
December 22, 2022
First Submitted That Met QC Criteria
January 10, 2023
First Posted (Actual)
January 11, 2023
Study Record Updates
Last Update Posted (Actual)
April 3, 2024
Last Update Submitted That Met QC Criteria
April 2, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OC-01-21001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on T-cell Acute Lymphoblastic Leukemia
-
Fundamenta Therapeutics, Ltd.The First Affiliated Hospital of University of Science and Technology of...RecruitingT-Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Therapeutic Advances in Childhood Leukemia ConsortiumGlaxoSmithKline; NovartisTerminatedRelapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic LymphomaUnited States, France, Canada, Australia, Austria, Italy, Netherlands
-
Ehab L AtallahRecruitingAcute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic LeukemiaUnited States
-
Beijing GoBroad HospitalNot yet recruitingAcute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
-
Shenzhen Geno-Immune Medical InstituteRecruitingT-Cell Acute Lymphoblastic LeukemiaChina
-
Beijing Boren HospitalRecruitingT-Cell Acute Lymphoblastic LeukemiaChina
-
Bambino Gesù Hospital and Research InstituteNot yet recruitingT-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
-
Beijing Boren HospitalRecruitingT-Cell Acute Lymphoblastic Leukemia/LymphomaChina
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingRefractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on CD1a-CAR T
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
Nexcella Inc.Not yet recruitingLight Chain (AL) AmyloidosisUnited States
-
Bellicum PharmaceuticalsSuspendedHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein OverexpressionUnited States
-
Chunrui LiNanjing IASO Biotechnology Co., LtdRecruitingPlasma Cell Leukemia | Relapsed/Refractory Multiple MyelomaChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom